AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
AbbVie (NYSE: ABBV) announced that CEO Robert A. Michael will assume the additional position of chairman, effective July 1, 2025, following the retirement of current chairman Richard A. Gonzalez. The board of directors unanimously elected Michael to the position, with lead independent director Roxanne S. Austin expressing complete confidence in his leadership.
Gonzalez, who has served as chairman since AbbVie's formation in 2013 and was formerly the company's CEO, will retire from the board. Additionally, Glenn F. Tilton, who served as lead independent director from 2013 to 2024, will also retire from AbbVie's board effective July 1, 2025.
AbbVie (NYSE: ABBV) ha annunciato che il CEO Robert A. Michael assumerà la posizione aggiuntiva di presidente, a partire dal 1° luglio 2025, in seguito al ritiro dell'attuale presidente Richard A. Gonzalez. Il consiglio di amministrazione ha eletto all'unanimità Michael per la posizione, con la direttrice indipendente principale Roxanne S. Austin che ha espresso piena fiducia nella sua leadership.
Gonzalez, che ha ricoperto il ruolo di presidente sin dalla fondazione di AbbVie nel 2013 ed è stato precedentemente CEO dell'azienda, si ritirerà dal consiglio. Inoltre, Glenn F. Tilton, che ha servito come direttore indipendente principale dal 2013 al 2024, si ritirerà anche lui dal consiglio di AbbVie a partire dal 1° luglio 2025.
AbbVie (NYSE: ABBV) anunció que el CEO Robert A. Michael asumirá la posición adicional de presidente, a partir del 1 de julio de 2025, tras la jubilación del actual presidente Richard A. Gonzalez. La junta directiva eligió unánimemente a Michael para el cargo, con la directora independiente principal Roxanne S. Austin expresando plena confianza en su liderazgo.
Gonzalez, quien ha sido presidente desde la formación de AbbVie en 2013 y fue anteriormente el CEO de la compañía, se retirará de la junta. Además, Glenn F. Tilton, quien fue director independiente principal de 2013 a 2024, también se retirará de la junta de AbbVie a partir del 1 de julio de 2025.
AbbVie (NYSE: ABBV)는 CEO 로버트 A. 마이클이 2025년 7월 1일부터 현재 의장인 리차드 A. 곤잘레즈의 은퇴에 따라 추가로 의장직을 맡게 된다고 발표했습니다. 이사회는 마이클을 이 자리에 만장일치로 선출했으며, 수석 독립 이사인 록산 S. 오스틴은 그의 리더십에 대한 완전한 신뢰를 표명했습니다.
곤잘레즈는 2013년 AbbVie 설립 이후 의장직을 수행해왔으며, 이전에는 회사의 CEO였습니다. 그는 이사회에서 은퇴할 예정입니다. 또한, 2013년부터 2024년까지 수석 독립 이사로 재직한 글렌 F. 틸턴도 2025년 7월 1일부터 AbbVie 이사회에서 은퇴할 것입니다.
AbbVie (NYSE: ABBV) a annoncé que le PDG Robert A. Michael assumera la position supplémentaire de président, à compter du 1er juillet 2025, suite à la retraite de l'actuel président Richard A. Gonzalez. Le conseil d'administration a élu Michael à l'unanimité, la directrice indépendante principale Roxanne S. Austin exprimant une confiance totale dans son leadership.
Gonzalez, qui a été président depuis la création d'AbbVie en 2013 et qui était auparavant le PDG de l'entreprise, se retirera du conseil. De plus, Glenn F. Tilton, qui a été directeur indépendant principal de 2013 à 2024, se retirera également du conseil d'AbbVie à compter du 1er juillet 2025.
AbbVie (NYSE: ABBV) gab bekannt, dass CEO Robert A. Michael ab dem 1. Juli 2025 die zusätzliche Position des Vorsitzenden übernehmen wird, nachdem der aktuelle Vorsitzende Richard A. Gonzalez in den Ruhestand geht. Der Vorstand wählte Michael einstimmig in die Position, wobei die leitende unabhängige Direktorin Roxanne S. Austin ihr volles Vertrauen in seine Führung zum Ausdruck brachte.
Gonzalez, der seit der Gründung von AbbVie im Jahr 2013 Vorsitzender ist und zuvor CEO des Unternehmens war, wird aus dem Vorstand ausscheiden. Darüber hinaus wird auch Glenn F. Tilton, der von 2013 bis 2024 als leitender unabhängiger Direktor tätig war, zum 1. Juli 2025 aus dem Vorstand von AbbVie ausscheiden.
- Smooth leadership transition with unanimous board support
- Consolidation of CEO and chairman roles under single leadership
- Continuity in leadership with internal succession
- Loss of experienced chairman Gonzalez after 12-year tenure
- Simultaneous departure of two senior board members (Gonzalez and Tilton)
- Richard A.
Gonzalez to retire from the board of directors effective July 1, 2025
"I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to have him assume the role of chairman. Rob is a visionary leader who operates with integrity and a steadfast commitment to AbbVie, its people, patients and shareholders. He is the right leader to guide this company into its next phase of growth."
"I am honored to take on the role of chairman," said Robert A. Michael, chief executive officer. "On behalf of our employees around the world, I extend my sincere gratitude to Rick for his exceptional leadership over the past 12 years. I look forward to partnering with the board to build on AbbVie's track record of success and to make a remarkable impact for our patients, employees, shareholders and communities."
"I am deeply grateful to the board for their strategic vision and support over the past 12 years," said Richard A.
In addition, Glenn F.
About Robert A. Michael
Mr. Michael is AbbVie's chief executive officer (CEO). Prior to being named CEO, Mr. Michael was president and chief operating officer of AbbVie and has been a longstanding member of the Company's Executive Leadership Team. From establishing AbbVie's first financial planning organization, to developing its diversified business strategy, to successfully navigating the end of exclusivity for Humira in the
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Media: Jackie Pacelli (224) 358-8128 jaquelin.pacelli@abbvie.com | Investors: Liz Shea (847) 935-2211 liz.shea@abbvie.com |
View original content:https://www.prnewswire.com/news-releases/abbvie-appoints-ceo-robert-a-michael-as-chairman-of-the-board-of-directors-302377064.html
SOURCE AbbVie
FAQ
When will Robert A. Michael become chairman of ABBV?
Who is retiring from AbbVie's board of directors in 2025?
How long did Richard Gonzalez serve as ABBV's chairman?
Who is the new lead independent director of ABBV?
